Physician profile
David P Rawdon
NPI 1376549139
$19,673.11
in general payments reported to CMS, 2019-2025
59 companies · $955 in 2025
The $955 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,841 · 2020: $2,826 · 2021: $3,193 · 2022: $3,273 · 2023: $3,547 · 2024: $3,037 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,500 · Education: $39.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,500.00 |
| Education | $39.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,369.26 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $2,107.43 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $1,885.41 | 2019-2025 | |
| Novo Nordisk INC | $1,662.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,612.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,509.12 | 2019-2025 | |
| Allergan, INC. | $952.27 | 2019-2020 | |
| Abbott Laboratories | $702.40 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $631.65 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Glaxosmithkline, LLC. | $418.01 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $404.10 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.70 | 2019-2024 | Jardiance, Tradjenta, Trijardy Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $383.15 | 2022 | |
| Amgen INC. | $361.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Tris Pharma INC | $237.90 | 2023-2024 | Dyanavel Xr |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rawdon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.